This is a specific type of lipodystrophy that is present from birth. It causes a severe lack of fat all over the body. People with this condition often have trouble controlling their blood sugar and have very high levels of fat in their blood.
Every report comes from a Lived member, sent anonymously.
Have you tried Insulin for Congenital Generalized Lipodystrophy?
Congenital generalized lipodystrophy (CGL), also called Berardinelli-Seip syndrome, is a rare inherited condition in which the body has almost no fat tissue from birth or early infancy. Fat tissue does more than cushion and insulate: it is where the body safely stores excess energy, and it releases hormones, including leptin, that help control appetite and how the body handles sugar and fat. Without it, fat ends up stored in places where it does harm, especially the liver and muscles. That misplaced fat drives the condition's main problems. Most people develop severe insulin resistance, meaning the body needs far more insulin than usual to keep blood sugar in range, and many go on to diabetes, sometimes in childhood. Blood triglycerides (a type of fat in the blood) are often extremely high, which can cause small yellow bumps in the skin and inflammation of the pancreas (pancreatitis). Fat buildup in the liver can enlarge it and, over time, scar it. The heart, kidneys and reproductive hormones can also be affected. People with CGL have a recognizable appearance: a very muscular build, prominent veins, a prominent belly button, large hands and feet, and often dark, velvety skin in body folds (acanthosis nigricans), a sign of high insulin levels. Children typically have an intense, hard-to-satisfy appetite. CGL is extremely rare, estimated at about 1 in 10 million people worldwide, with clusters in parts of Brazil and Lebanon.
CGL is genetic. It follows an autosomal recessive pattern: a child is affected only when they inherit a nonworking copy of the same gene from each parent. The parents are usually healthy carriers, and each of their children has a 1 in 4 chance of being affected. It is not caused by diet, weight or anything that happened during pregnancy. Four genes are known, and each defines a type with some distinctive features. Type 1 (AGPAT2) can cause bone cysts in the arms and legs after puberty. Type 2 (BSCL2) tends to be the most severe metabolically, carries a high risk of early liver scarring and can be associated with mild to moderate intellectual disability. Type 3 (CAV1) is linked to poor growth and short stature. Type 4 (CAVIN1) can involve muscle weakness, developmental delay and serious heart rhythm problems. Some people with CGL have no change found in any of these genes, so other causes likely remain to be discovered.
There are no fixed diagnostic criteria. Doctors make the diagnosis from the overall picture: a near-total lack of body fat beginning at birth or in infancy, the typical physical features, and blood tests showing insulin resistance, diabetes, high triglycerides or fatty liver. Measurements of fat (skinfold thickness, a low-dose X-ray body-composition scan called dual-energy X-ray absorptiometry (DEXA), or whole-body MRI) can document how little fat is present. Baby photographs can help, because infants with CGL usually look lean from the start. Genetic testing confirms the diagnosis and identifies the type, which helps predict which complications to watch for. A negative genetic test does not rule CGL out, because not all causes are known. Blood leptin levels are not reliable for making the diagnosis, although they can help guide treatment choices. Part of the assessment is ruling out conditions that can look similar, including severe weight loss from uncontrolled diabetes, overactive thyroid or chronic illness, and acquired generalized lipodystrophy, a noninherited form in which fat is lost later in childhood. Once a diagnosis is made, genetic counseling and testing of siblings and other at-risk relatives are usually offered.
There is no treatment that can regrow fat tissue, so care focuses on preventing and controlling the complications. It is usually led by an endocrinologist with experience in lipodystrophy, working with a dietitian. Diet is the foundation. A balanced diet that limits simple sugars, favors high-fiber carbohydrates and healthier fats, and avoids overeating lowers blood sugar and triglycerides. This is hard because of the strong appetite leptin deficiency causes. In children, food limits have to be balanced against what they need to grow, and the goal is steady growth in height rather than a normal weight on a standard growth chart; trying to add weight can worsen fatty liver. Infants with very high triglycerides may use a special formula based on medium-chain triglyceride oil. Metreleptin (Myalept) is a lab-made version of leptin, given as a daily injection under the skin. It is the only medicine approved in the US specifically for generalized lipodystrophy, as an add-on to diet, and it can be started in young children. It replaces the missing hormone: hunger usually eases, and over months blood sugar, triglycerides and liver fat typically improve. In studies, HbA1c (a measure of average blood sugar over about three months) fell by about 2 percentage points and triglycerides by about 60% after a year, and many young people with CGL were able to stop insulin. Because blood sugar can drop quickly once treatment starts, insulin doses often need to be cut and glucose checked closely. Stopping or sharply reducing metreleptin suddenly can cause triglycerides to rebound and trigger pancreatitis. The drug carries a boxed warning: some people develop antibodies that may reduce its effect, and lymphoma has been reported in people with the acquired form of lipodystrophy. Because of these risks, it is available only through a restricted program with certified prescribers and pharmacies. Standard medicines treat individual problems: metformin and, often, high doses of insulin for diabetes; statins, fibrates and fish-oil omega-3s for cholesterol and triglycerides (statins and fibrates need watching for muscle side effects); and blood pressure medicines called angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers. One medicine group needs special mention: estrogen taken by mouth, including combined birth control pills, can trigger dangerous triglyceride rises and pancreatitis in lipodystrophy, so progestin-only or nonhormonal contraception is preferred, and estrogen, when needed, is given through the skin. Support from mental health professionals, and sometimes cosmetic procedures such as facial fillers, can help with distress about appearance.
CGL is lifelong and needs ongoing specialist care. How it affects daily life depends a great deal on the genetic type and on how well blood sugar, triglycerides and liver fat are controlled. For many people, daily life involves a carefully planned diet, blood sugar checks, and either injections of metreleptin or insulin, or both. Regular screening is a core part of care, because serious complications can develop silently. Guidelines recommend checking for diabetes, cholesterol and triglycerides, liver function and urine protein (an early sign of kidney damage) at least once a year, along with blood pressure, which is often high even in children. Because heart muscle disease and rhythm problems can occur, an ECG (a heart rhythm tracing) and an echocardiogram (a heart ultrasound) are recommended every year. On metreleptin, people are typically reviewed every 3 to 6 months. Children may go through puberty early or late, and girls and women often have irregular periods, extra body hair or polycystic ovaries, with reduced fertility. Metreleptin can help normalize puberty and periods. Pregnancy is possible but makes insulin resistance worse, so it calls for planning and care from an obstetrician experienced in diabetes together with the lipodystrophy team. Outlook varies. Without good control, complications can shorten life: in one study of people with CGL in Brazil who died between 1997 and 2017, the average age at death was about 27, most often from infections or liver disease. Those patients were largely treated before metreleptin was widely available, and how much modern treatment changes long-term survival is not yet known. Early diagnosis and steady control of the metabolic problems give the best chance of protecting the liver, heart and kidneys.
Ask for a specialist evaluation if a baby or child has very little visible fat, an unusually muscular look and prominent veins, an extreme appetite, or diabetes, very high triglycerides or an enlarged liver at a young age. Relatives of someone with CGL may want genetic counseling before planning a family. Contact the care team promptly about frequent low blood sugar readings (especially after starting or changing metreleptin or insulin), missed or interrupted metreleptin supplies, rising blood sugar or triglycerides despite treatment, new swelling or breathlessness, or a planned or possible pregnancy. Intense, constant pain in the upper abdomen, often with vomiting, can be pancreatitis from very high triglycerides and needs urgent medical assessment the same day.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Congenital Generalized Lipodystrophy is like, what's helped you, or ask the community a question.